Join Now | Sign in

Arterial Hypertension Health Article

Marketplace

Licensed from

Page: < Back 1 2 3 4 5 6 7

References

1 PK Whelton LJ Appel MA Espeland Sodium reduction and weight loss in the treatment of hypertension in older persons'A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE) JAMA 279 1998 839 846
2 FM Sacks LP Svetkey WM Vollmer Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group N Engl J Med 344 2001 3 10
3 X Xin J He MG Frontini Effects of alcohol reduction on blood pressure: A meta-analysis of randomized controlled trials Hypertension 38 2001 1112 1117
4 N Taylor-Tolbert D Dengel M Brown Ambulatory blood pressure after acute exercise in older men with essential hypertension Am J Hypertens 13 2000 44 51
5 JA Staessen JG Wang L Thijs Cardiovascular protection and blood pressure reduction: A meta-analysis Lancet 358 2001 1305 1315
6 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme Inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
7 WC Cushman CE Ford JA Cutler Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) J Clin Hypertens 4 2002 393 404
8 JA Staessen J Gasowski JG Wang Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials Lancet 355 2000 865 872
9 Blood Pressure Lowering Treatment Trialists' Collaboration Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomized trials Lancet 356 2000 1955 1964
10 EJ Lewis LG Hunsicker WR Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
11 JT Wright Jr G Bakris T Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial JAMA 288 2002 2421 2431
12 BM Brenner ME Cooper D de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
13 H-H Parving H Lehnert J Brochner-Mortensen Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
14 ALLHAT Officers and Coordinators Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 283 2000 1967 1975
15 AI Adler IM Stratton HA Neil Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study BMJ 321 2000 409 412
16 L Liu JG Wang L Gong Comparison of active treatment and placebo for older patients with isolated systolic hypertension J Hypertens 16 1998 1823 1829
17 J Tuomilehto D Rastenyte WH Birkenhager Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators N Engl J Med 340 1999 677 684
18 PROGRESS Collaborative Group Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041

Suggested Readings

August, 2003 P August Initial treatment of hypertension N Engl J Med 348 2003 610 617 A practical review.
Chobanian et al., 2003 A Chobanian G Bakris H Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report JAMA 289 2003 2560 2572 The latest consensus guidelines.
Kaplan, 2002 NM Kaplan Kaplan's Clinical Hypertension 8th ed. 2002 Williams & Wilkins Baltimore A lucid, updated text.
Lifton et al., 2001 RP Lifton AG Gharavi DS Geller Molecular mechanisms of human hypertension Cell 164 2001 545 556 A review of the molecular genetics of human hypertension.
Psaty et al., 2003 BM Psaty T Lumley CD Furberg Health outcomes associated with various anti-hypertensive therapies used as first-line agents: A network meta-analysis JAMA 289 2003 2534 2544 Low-dose diuretics were the most effective first-line treatment.
Wing et al., 2003 LM Wing CM Reid P Ryan A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly N Engl J Med 348 2003 583 592 ACE inhibitors were better than diuretics in the elderly.